PrimeC is a disease-modifying drug designed to slow ALS progression by addressing motor neuron degeneration, inflammation, and multiple ALS pathways, including microRNA regulation and iron accumulation.
The page explains how to evaluate ALS breakthrough therapy claims by examining disease biology, treatment goals, and the credibility of multi-target strategies over single-pathway approaches.
NeuroSense’s combination therapy targets Alzheimer’s disease through multiple pathways, including reducing inflammation, oxidative stress, and Aβ aggregation. The company is enrolling patients in the RoAD Phase 2 study at Rambam Health Care Campus.
“Seeing how an individual living with ALS could benefit so much from the technology I helped create, I was inspired to dedicate myself to finding a remedy for ALS and other neurodegenerative diseases”.
NeuroSense Therapeutics is a late-stage clinical biotech company developing targeted treatments for neurodegenerative diseases. Founded in 2017 by Alon Ben-Noon, it originated from a meeting with Shay Rishoni, a person living with ALS.
